Manufacturers increasingly have been implementing restrictions on covered entities’ contract pharmacy use to prevent diversion and duplicate discounts, safeguard program integrity and promote transparency. Given variability in manufacturer policies and impact on covered entity revenue, it is critical for manufacturers to understand account response strategy and willingness to implement access restrictions on impacted and portfolio products.
This syndicated report covers:
- 340B drug pricing program overview and trends
- Contract pharmacy restriction impact on covered entity revenue and operations
- Contract pharmacy restriction policy dynamics
- Mistaken 340B pricing blocks, stakeholders and access impact
View the Infographic